Entrada Therapeutics (TRDA) Competitors $19.96 -0.21 (-1.04%) (As of 12/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRDA vs. TWST, VCEL, BHC, MOR, IOVA, GMTX, ACAD, AMRX, CPRX, and PTGXShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Twist Bioscience (TWST), Vericel (VCEL), Bausch Health Companies (BHC), MorphoSys (MOR), Iovance Biotherapeutics (IOVA), Gemini Therapeutics (GMTX), ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Twist Bioscience Vericel Bausch Health Companies MorphoSys Iovance Biotherapeutics Gemini Therapeutics ACADIA Pharmaceuticals Amneal Pharmaceuticals Catalyst Pharmaceuticals Protagonist Therapeutics Twist Bioscience (NASDAQ:TWST) and Entrada Therapeutics (NASDAQ:TRDA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings. Which has more risk & volatility, TWST or TRDA? Twist Bioscience has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Do analysts rate TWST or TRDA? Twist Bioscience currently has a consensus target price of $51.00, indicating a potential upside of 0.77%. Entrada Therapeutics has a consensus target price of $24.00, indicating a potential upside of 18.99%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TWST or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Twist Bioscience's net margin of -66.69%. Entrada Therapeutics' return on equity of 16.11% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-66.69% -32.27% -25.37% Entrada Therapeutics 25.53%16.11%10.39% Do insiders and institutionals hold more shares of TWST or TRDA? 86.4% of Entrada Therapeutics shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, TWST or TRDA? Entrada Therapeutics has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M9.60-$208.73M-$3.60-14.06Entrada Therapeutics$129.01M5.85-$6.68M$1.5912.69 Does the media prefer TWST or TRDA? In the previous week, Twist Bioscience had 2 more articles in the media than Entrada Therapeutics. MarketBeat recorded 7 mentions for Twist Bioscience and 5 mentions for Entrada Therapeutics. Twist Bioscience's average media sentiment score of 1.19 beat Entrada Therapeutics' score of 0.15 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor TWST or TRDA? Twist Bioscience received 84 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Entrada Therapeutics an outperform vote while only 58.82% of users gave Twist Bioscience an outperform vote. CompanyUnderperformOutperformTwist BioscienceOutperform Votes10058.82% Underperform Votes7041.18% Entrada TherapeuticsOutperform Votes1680.00% Underperform Votes420.00% SummaryEntrada Therapeutics beats Twist Bioscience on 11 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$760.37M$6.72B$5.21B$9.01BDividend YieldN/A7.94%5.36%4.00%P/E Ratio12.698.45119.0416.54Price / Sales5.85327.601,270.0081.91Price / CashN/A59.1741.9838.55Price / Book2.785.534.884.92Net Income-$6.68M$152.51M$119.93M$224.30M7 Day Performance1.71%-0.30%0.48%0.68%1 Month Performance13.51%-2.26%0.58%6.78%1 Year Performance47.77%27.11%32.25%27.66% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics1.7284 of 5 stars$19.96-1.0%$24.00+20.2%+50.5%$746.90M$129.01M12.55110Insider TradeTWSTTwist Bioscience3.4802 of 5 stars$49.59+0.8%$51.00+2.8%+104.2%$2.94B$312.97M-13.66990Positive NewsVCELVericel1.4119 of 5 stars$58.94+1.4%$59.71+1.3%+63.5%$2.91B$197.52M979.16300Insider TradeBHCBausch Health Companies3.5398 of 5 stars$8.01-4.3%$7.75-3.2%+9.9%$2.88B$8.76B-17.4420,270Positive NewsMORMorphoSysN/A$18.96flat$12.38-34.7%N/A$2.86B$238.28M-5.45730IOVAIovance Biotherapeutics4.4089 of 5 stars$9.12-2.1%$22.33+144.9%+39.5%$2.78B$1.19M-6.25500Short Interest ↓GMTXGemini TherapeuticsN/A$63.45-1.7%N/A+15.2%$2.75BN/A-63.4530ACADACADIA Pharmaceuticals4.0419 of 5 stars$16.51+1.2%$25.56+54.8%-27.9%$2.75B$726.44M20.69510Short Interest ↑Analyst RevisionPositive NewsAMRXAmneal Pharmaceuticals1.7479 of 5 stars$8.67+4.8%$10.00+15.3%+83.0%$2.69B$2.39B-12.167,700CPRXCatalyst Pharmaceuticals4.8988 of 5 stars$22.07-1.2%$31.14+41.1%+46.5%$2.63B$398.20M18.70167Short Interest ↓Analyst RevisionPTGXProtagonist Therapeutics2.7578 of 5 stars$42.82-2.2%$53.57+25.1%+122.3%$2.55B$60M16.47125 Related Companies and Tools Related Companies Twist Bioscience Alternatives Vericel Alternatives Bausch Health Companies Alternatives MorphoSys Alternatives Iovance Biotherapeutics Alternatives Gemini Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRDA) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis frightening chart explains everything going on in the economy (see photo)Why the wealth gap is getting wider — with the one percenters growing ever richer and ever more powerful, whil...Banyan Hill Publishing | SponsoredExpert: The most important message you’ll see in 2024The message I'm sharing today could be the most important message of 2024. In short, America is being invad...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts